Last checked at 21 Dec 2017 07:00
OXFORD BIODYNAMICS PLC
PDMR DEALINGS/EXERCISE OF SHARE OPTIONS
TOTAL VOTING RIGHTS
London, 21 December 2017: Oxford BioDynamics Plc (AIM: OBD) (the "Company") announces that it has received notices of exercise of options under the Company's 2008 Enterprise Management Incentive Share Option Scheme from Dr Alexandre Akoulitchev, (Chief Scientific Officer) and Dr Aroul Ramadass (Chief Technology Officer) to subscribe for 346,152 and 346,152 Ordinary Shares of 1 pence each in the Company respectively (the "New Ordinary Shares"). The exercise price of the options is 34 pence each.
Following the exercise of these options, Dr Alexandre Akoulitchev owns 6,153,082 Ordinary Shares, representing approximately 7.03% of the Company's enlarged issued share capital, and Dr Aroul Ramadass and family owns 5,830,468 Ordinary Shares, representing approximately 6.66% of the Company's enlarged issued share capital.
Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on or around 2 January 2018. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue.
Following issue of the New Ordinary Shares, the Company's total issued share capital will consist of 87,479,973 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 87,479,973. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Dr Alexandre Akoulitchev |
2 | Reason for the notification | |
a) | Position/status | Chief Scientific Officer/Director/PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Share options exercise |
c) | Price(s) and volume(s) | 346,152 Ordinary Shares at a price of 34 pence per share |
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 20 December 2017
|
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Dr Aroul Ramadass |
2 | Reason for the notification | |
a) | Position/status | Chief Technology Officer/PDMR |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Oxford BioDynamics Plc |
b) | LEI | 2138005Y1TK258O5U928 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
b) | Nature of the transaction | Share options exercise |
c) | Price(s) and volume(s) | 346,152 Ordinary Shares at a price of 34 pence per share |
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 20 December 2017
|
f) | Place of the transaction | Outside a trading venue |
For further details, contact:
Oxford BioDynamics Plc | +44 (0)1865 518910 | |
Christian Hoyer Millar, CEO | ||
Paul Stockdale, CFO | ||
Stifel Nicolaus Europe Limited | +44 (0)20 7710 7600 | |
Nominated Advisor and Broker | ||
David Arch | ||
Jonathan Senior | ||
Peter Lees | ||
Ben Maddison | ||
Shore Capital | +44 (0)20 7408 4090 | |
Joint Broker | ||
Edward Mansfield | ||
Stephane Auton
| ||
FTI Consulting | +44 (0)20 3727 1000 | |
Financial Public Relations Advisor | ||
Julia Phillips | ||
Brett Pollard | ||
Natalie Garland-Collins
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.